« Back

Steven Perrin, PhD

Dr. Perrin was the Founder and Chief Executive Officer of Anelixis Therapeutics, Inc. before joining Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.) He has 20 years of drug development experience, having held R&D positions at the Hoechst-Ariad Genomics Center, Aventis Pharmaceuticals, Inc., and Biogen Idec, Inc. Over the past decade, Dr. Perrin has worked with the ALS Therapy Development Institute to develop the world’s largest ALS drug development program, bridging preclinical and clinical programs. Dr. Perrin earned a Ph.D. in Biochemistry from Boston University Medical Center, where he also started his career as Associate Professor of Medicine, and a Bachelor of Science from Boston College.